Those men who are suffering from erectile dysfunction or premature ejaculation can look forward to a potential instantaneous remedy that works in 10 ten minutes following inhalation of the drug soon.
The great benefit of the drug is that it can be directly inhaled through nostrils just like an asthma inhaler and no need to swallow pills or painful injections.
The experimental drug code-named VR004 also gives results very quickly – in minutes – unlike the current erectile dysfunction pills like Viagra which needs to be swallowed atleast half an hour before sexual intercourse.
VR004 contains a powdered form of a drug called apomorphine.
Apomorphine using the inhalation route may offer an effective and convenient alternative.
There are a number of treatments available currently against erectile dysfunction. Drugs like sildenafil (Viagra) via the oral route, injections prior to intercourse, vacuum pumps, hormone treatment or, more rarely, surgery, all of which take time to take action, are invasive or inconvenient.
Erectile dysfunction pills such as Viagra, Cialis and Levitra may fail to give an effect in nearly 30 percent of men who take them.
Study results involving 600 men showed majority of men using an inhaler of the powdered apomorphine could get an erection within 10 minutes.
Apomorphine is a potent, short-acting dopamine agonist that stimulates dopamine receptors in the corpus striatum of the brain. It has been originally developed for Parkinson’s disease treatment.
When inhaled, ultra-low dose apomorphine has the potential to provide rapid benefit to patients with mild, moderate and severe erectile dysfunction or ED, according to the developer of the drug Vectura.
Apomorphine has been approved previously in Europe for ED as a sublingual tablet.
VR004 is formulated in a proprietary Vectura formulation, delivered using Vectura’s Aspirair device.
Around one in ten men will experience recurring impotence problems at some point in their lives, resulting in a considerable potential market for a rapid-onset treatment with few or no side effects.
Vectura is also developing an inhalable drug for premature ejaculation (PE).
Code-named VR776, the drug is a proprietary, inhaled, systemic treatment for premature ejaculation (PE) in which the active ingredient is an off-patent neuro-active drug approved worldwide for the treatment of other indications.
The active constituent of VR776 is thought to act via 5-HT and noradrenergic-mediated pathways in the brain.
These neurotransmitters are involved in the central control of ejaculation by activating and inhibiting 5-HT receptor subtypes.
VR776 is formulated using PowderHale and is delivered with Aspirair.
Around 50 million males over the age of 40 are estimated to be affected by PE in the US and Europe.
Currently no product is marketed in the United States or Europe specifically for the treatment of premature ejaculation.
Vectura believes that the lack of a licensed drug that specifically addresses PE, the high incidence of PE and the increasing willingness of patients to present with this problem will mean that this is an important future market for effective pharmaceutical products.
Erectile dysfunction, sometimes called “impotence,” is the repeated inability to get or keep an erection firm enough for sexual intercourse.
Erectile dysfunction, or ED, can be a total inability to achieve erection, an inconsistent ability to do so, or a tendency to sustain only brief erections.
In older men, ED usually has a physical cause, such as disease, injury, or side effects of drugs.
Any disorder that causes injury to the nerves or impairs blood flow in the penis has the potential to cause ED.
Incidence increases with age: About 5 percent of 40-year-old men and between 15 and 25 percent of 65-year-old men experience ED. But it is not an inevitable part of aging.
ED is treatable at any age, and awareness of this fact has been growing.